Nephros (NASDAQ:NEPH) Stock Rating Upgraded by Wall Street Zen

Nephros (NASDAQ:NEPH) was upgraded by stock analysts at Wall Street Zen to a “strong-buy” rating in a research note issued on Saturday.

Other equities research analysts have also recently issued research reports about the stock. Maxim Group lifted their target price on shares of Nephros from $4.50 to $6.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Nephros in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Nephros Price Performance

Shares of NASDAQ:NEPH opened at $4.89 on Friday. The business’s 50 day moving average price is $4.44 and its 200-day moving average price is $3.48. Nephros has a 1 year low of $1.36 and a 1 year high of $5.98. The firm has a market capitalization of $51.83 million, a price-to-earnings ratio of 40.75 and a beta of 1.32.

Nephros (NASDAQ:NEPH) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.04. Nephros had a net margin of 7.95% and a return on equity of 14.89%. The company had revenue of $4.40 million during the quarter, compared to analysts’ expectations of $3.60 million.

Institutional Trading of Nephros

A hedge fund recently raised its stake in Nephros stock. Geode Capital Management LLC raised its position in shares of Nephros Inc. (NASDAQ:NEPH) by 3.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 93,187 shares of the company’s stock after buying an additional 2,898 shares during the period. Geode Capital Management LLC owned about 0.88% of Nephros worth $381,000 as of its most recent filing with the Securities & Exchange Commission. 41.10% of the stock is owned by hedge funds and other institutional investors.

About Nephros

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.